Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients

Canadian Journal of Cardiology

Volumn 20, Issue 8, 2004, Pages 779-782

  Guo, Hangyuan ^a,b   Wang, Jian'an ^a   Chen, Junzhu ^a   Shan, Jiang ^a   Lee, Jong Dae ^b   Ueda, Takanori ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Follow up; Hypertrophic obstructive cardiomyopathy; Long term; Percutaneous transluminal septal myocardial ablation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; HEPARIN; VERAPAMIL; ALCOHOL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXTRASYSTOLE; FEMALE; FOLLOW UP; HEART BLOCK; HEART CATHETERIZATION; HEART LEFT VENTRICLE OUTFLOW TRACT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LONG TERM CARE; MALE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; CATHETER ABLATION; CLINICAL TRIAL; COMPARATIVE STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE SEPTUM; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 3242809100     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gleichmann U, Seggewiss H. Clinical Picture and therapy of hypertrophic cardiomyopathy. Med Klin 1998;93:260-7.
2. Meisel E, Rauwolf T, Burghardt M, et al, for the PIC (Pacing in Cardiomyopathy) Study Group. [Pacemaker therapy of hypertrophic obstructive cardiomyopathy.] Herz 2000;25:461-6.
3. Kuhn H, Gietzen FH, Schafers M, et al. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 1999;20:1808-17.
4. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2001;3:160-6.
5. Veselka J, Honek T. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol 2003;88:27-32.
6. Airoldi F, Di Mario C, Catanoso A, et al. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 2000; 1:200-6.
7. Mutlak D, Gruberg L, Reisner S, et al. Non-Surgical myocardial reduction in hypertrophic obstructive cardiomyopathy. Isr Med Assoc J 2002;4:86-90.
8. Sigwart U. Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
9. Jiang T, Wu X, Jia C, et al. Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy. Chin Med J (Engl) 2002; 115:26-30.
10. Jiang T, Wu X, Jia C. Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy: Immediately and middle-term follow-up results. Zhonghua Nei Ke Za Zhi 2001;40:663-5.
11. Rubin DN, Tuzcu EM, Lever HM. Percutaneous transluminal septal myocardial ablation. Curr Cardiol Rep 2000;2:160-5.
12. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100.
13. Zhang W, Li Z, Zhang M, et al. Complications of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Chin Med J (Engl) 2002;115:1283-6.
14. Faber L, Seggewiss H, Ziemssen P, et al. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv 1999;47:462-6.
15. Kar S, Makkar R. Percutaneous transluminal septal myocardial ablation: A novel, nonsurgical treatment for symptomatic hypertrophic cardiomyopathy. Rev Cardiovasc Med 2001;2:97-102.
16. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998;98:2415-21.